Organization
United Therapeutics
26 clinical trials
Clinical trial
Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment SatisfactionStatus: Terminated, Estimated PCD: 2009-09-01
Clinical trial
DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter StudyStatus: Completed, Estimated PCD: 2011-03-01
Clinical trial
Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension in the Outpatient Clinic: Safety, Efficacy and Treatment SatisfactionStatus: Terminated, Estimated PCD: 2010-01-01
Clinical trial
A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial HypertensionStatus: Completed, Estimated PCD: 2011-04-01
Clinical trial
An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®Status: Completed, Estimated PCD: 2013-11-01
Clinical trial
TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)Status: Completed, Estimated PCD: 2014-02-25
Clinical trial
EVOLVE: A Virtual, Observational, Patient-Centric Prospective Study to Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin to Patients With Pulmonary Arterial HypertensionStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial HypertensionStatus: Completed, Estimated PCD: 2007-10-01
Clinical trial
A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction)Status: Recruiting, Estimated PCD: 2024-09-12
Clinical trial
A Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15C SR (Treprostinil Diethanolamine) in the TDE-PH-304 ProtocolStatus: Completed, Estimated PCD: 2013-11-01
Clinical trial
An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)Status: Terminated, Estimated PCD: 2022-11-29
Clinical trial
Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy StudyStatus: Terminated, Estimated PCD: 2022-09-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using TyvasoStatus: Completed, Estimated PCD: 2023-08-22
Clinical trial
A Single Center, Randomized, Double-Blind, Parallel Placebo-Controlled Study of the Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant RecipientsStatus: Withdrawn, Estimated PCD: 2010-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)Status: , Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
ADAPT - A Patient Registry of the Real-world Use of Orenitram®Status: Active (not recruiting), Estimated PCD: 2022-04-07
Clinical trial
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung DiseaseStatus: Terminated, Estimated PCD: 2021-08-01
Clinical trial
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial HypertensionStatus: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)Status: Terminated, Estimated PCD: 2022-10-13
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated TherapyStatus: Terminated, Estimated PCD: 2023-04-12
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAHStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisStatus: , Estimated PCD: 2024-06-01
Clinical trial
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: An Open-label Multicenter Extension StudyStatus: Terminated, Estimated PCD: 2011-09-01